Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(PRESELECT-0) | recruiting | Phase 2 | 18 | The University of Hong KongOTHER | 1 | Jul 2, 2025 |
| NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(Preselect-1) | recruiting | Phase 2 | 126 | The University of Hong KongOTHER | 2 | Jul 2, 2025 | clinicaltrials |
| NCT07039331 | Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients(DIETA) | recruiting | N/A | 54 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07044349 | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not yet recruiting | Phase 2 | 72 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Jun 30, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06817174 | Ovarian Cancer Radiomics Approach in CT Led Evaluation(ORACLE) | recruiting | — | 168 | Imperial College Healthcare NHS TrustOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06139783 | Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors | not yet recruiting | N/A | 32 | Oncare MadridOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07035587 | Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques | recruiting | — | 1,200 | Yonsei UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06954584 | Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | recruiting | Phase 3 | 424 | Tongji HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06977594 | Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer | not yet recruiting | N/A | 1,000 | Seoul National University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07031908 | Minimally Invasive Interval Debulking Surgery in Advanced Ovarian Cancer(MISSION-2) | not yet recruiting | — | 40 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028229 | Ultrasound Training Program for Gynecologic Cancer Staging in Residents(Ultra-teaching) | not yet recruiting | N/A | 6 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02288676 | DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics(DOvEEgene) | recruiting | — | 1,200 | McGill UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | active not recruiting | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06564428 | A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration | recruiting | — | 1,000 | Peking University Third HospitalOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06292286 | Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer(SCENIC) | recruiting | N/A | 18 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT01953159 | Assessment of Paclitaxel-Induced Neuropathy | active not recruiting | — | 43 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009743 | O-RADS MRI System on Early Detection of Ovarian Cancer | active not recruiting | — | 2,549 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05740956 | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 318 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Weijia Fang, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 300 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06988280 | Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions(UTAC) | recruiting | — | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06129968 | Transforming Ovarian Cancer Diagnostic Pathways(SONATA) | recruiting | — | 34,000 | Professor Sudha SundarOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05156892 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer(TICTOC) | active not recruiting | Phase 1 | 44 | Anthony Joshua, FRACPOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06973421 | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 35 | Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | recruiting | Phase 2 | 150 | AkesoINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06925126 | Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer | not yet recruiting | — | 200 | Fudan UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06907771 | Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer(PACO) | recruiting | — | 130 | University Hospital, Strasbourg, FranceOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06902467 | Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)(BICOV) | recruiting | N/A | 20 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)(NICHOL) | recruiting | Phase 1 / Phase 2 | 73 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06689605 | Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.(TRUCUTOC) | recruiting | — | 30 | University Hospital Hradec KraloveOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06883409 | Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer | recruiting | N/A | 33 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06890858 | A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer | recruiting | Phase 2 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06887933 | A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 4 | 67 | GlaxoSmithKlineINDUSTRY | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06887673 | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | not yet recruiting | Early Phase 1 | 56 | University of South FloridaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06884345 | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06871787 | Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery(INOCA) | not yet recruiting | Phase 4 | 50 | Istanbul UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2025source: clinicaltrials